ATE245662T1 - Avidin-biotin immunokonjugate - Google Patents

Avidin-biotin immunokonjugate

Info

Publication number
ATE245662T1
ATE245662T1 AT95910893T AT95910893T ATE245662T1 AT E245662 T1 ATE245662 T1 AT E245662T1 AT 95910893 T AT95910893 T AT 95910893T AT 95910893 T AT95910893 T AT 95910893T AT E245662 T1 ATE245662 T1 AT E245662T1
Authority
AT
Austria
Prior art keywords
biotin
viral vector
cell
immunoconjugates
avidin
Prior art date
Application number
AT95910893T
Other languages
English (en)
Inventor
Michael G Rosenblum
Nicholas J Donato
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE245662T1 publication Critical patent/ATE245662T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT95910893T 1994-02-07 1995-02-06 Avidin-biotin immunokonjugate ATE245662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19265594A 1994-02-07 1994-02-07
PCT/US1995/001161 WO1995021195A1 (en) 1994-02-07 1995-02-06 Non-viral vector

Publications (1)

Publication Number Publication Date
ATE245662T1 true ATE245662T1 (de) 2003-08-15

Family

ID=22710534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95910893T ATE245662T1 (de) 1994-02-07 1995-02-06 Avidin-biotin immunokonjugate

Country Status (16)

Country Link
US (1) US6214974B1 (de)
EP (1) EP0743958B1 (de)
JP (1) JP4015693B2 (de)
KR (1) KR100376390B1 (de)
CN (1) CN1200950C (de)
AT (1) ATE245662T1 (de)
AU (1) AU695564B2 (de)
CA (1) CA2182616A1 (de)
DE (1) DE69531342D1 (de)
FI (1) FI963103A7 (de)
IL (1) IL112372A (de)
NO (1) NO319899B1 (de)
NZ (1) NZ281763A (de)
RU (1) RU2164943C2 (de)
SA (1) SA95150519B1 (de)
WO (1) WO1995021195A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237688A (en) * 1990-04-19 1993-01-27 Res Dev Foundation Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
EP0756213B1 (de) * 1994-02-08 2002-12-04 Research Laboratories of Australia Pty Limited Mehrfarbenbilderzeugungsgerät mit flüssigentwicklung
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
JP2002520369A (ja) * 1998-07-17 2002-07-09 アメリカ合衆国 水溶性薬剤およびその製造方法
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
GB9930533D0 (en) * 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
EP1404707A4 (de) * 2001-05-29 2005-02-02 Univ Michigan Systeme und verfahren zur analyse von proteinen
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1414471B1 (de) 2001-07-17 2012-06-13 Research Development Foundation Therapeutische Mittel mit pro-apoptotischen Proteinen
AU2002323845A1 (en) * 2002-04-02 2003-10-13 "Asgl-Farmatsevticheskie Innovatsii", Zakrytoe Aktsionernoe Obschestvo Recombinant chimeric protein for the target delivery of dna to eukariotic target cells
EP1572170A4 (de) * 2002-06-12 2007-02-28 Res Dev Foundation Immunotoxin als therapeutisches mittel und seine verwendungen
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CN101104856B (zh) * 2003-11-18 2010-11-10 中国医学科学院基础医学研究所 一个系列的非病毒载体及包含其的药物组合物
EP1855724A2 (de) * 2005-02-01 2007-11-21 Research Development Foundation Blys-fusionsproteine für targeting des blys-rezeptors und verfahren zur behandlung von proliferativen b-zell-störungen
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
RU2430740C2 (ru) * 2006-08-18 2011-10-10 Ф.Хоффманн-Ля Рош Аг Поликонъюгаты для введения in vivo полинуклеотидов
SG182170A1 (en) * 2007-06-06 2012-07-30 Domantis Ltd Polypeptides, antibody variable domains and antagonists
AR084020A1 (es) 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
AU2012253327B2 (en) 2011-05-11 2017-05-25 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3795168A1 (de) 2015-01-16 2021-03-24 City of Hope Zellendurchdringende antikörper
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CA3067587A1 (en) 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation Immunogenic compositions
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2019338448B2 (en) 2018-09-12 2026-02-26 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5510590A (en) * 1978-05-04 1980-01-25 Wellcome Found Enzyme immunity quantity analysis
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5026785A (en) * 1989-05-12 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP1138334A3 (de) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting Verfahren und Mitteln
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
JPH08510250A (ja) * 1993-05-17 1996-10-29 イムノメディクス，インコーポレイテッド ビオチンまたはアビジンと金属キレート化タンパク質との複合体による病変の検出および治療法の改善
DE69433343D1 (de) * 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln

Also Published As

Publication number Publication date
SA95150519B1 (ar) 2005-07-24
FI963103A0 (fi) 1996-08-06
AU1868795A (en) 1995-08-21
CA2182616A1 (en) 1995-08-10
US6214974B1 (en) 2001-04-10
KR970700771A (ko) 1997-02-12
EP0743958A1 (de) 1996-11-27
RU2164943C2 (ru) 2001-04-10
JPH09508792A (ja) 1997-09-09
EP0743958A4 (de) 1999-07-28
WO1995021195A1 (en) 1995-08-10
AU695564B2 (en) 1998-08-13
DE69531342D1 (de) 2003-08-28
IL112372A (en) 2001-08-26
NZ281763A (en) 2001-06-29
NO319899B1 (no) 2005-09-26
JP4015693B2 (ja) 2007-11-28
NO963283L (no) 1996-08-06
FI963103L (fi) 1996-10-01
KR100376390B1 (ko) 2003-06-12
FI963103A7 (fi) 1996-10-01
NO963283D0 (no) 1996-08-06
CN1143374A (zh) 1997-02-19
CN1200950C (zh) 2005-05-11
IL112372A0 (en) 1995-03-30
EP0743958B1 (de) 2003-07-23

Similar Documents

Publication Publication Date Title
ATE245662T1 (de) Avidin-biotin immunokonjugate
DK1075282T3 (da) PEG-LHRH-analog-konjugater
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
AU5266698A (en) Directional drug delivery stent
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
IL126714A (en) Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
EP0436664A4 (en) Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
FR2779429B1 (fr) Derives d'oxindole, leurs preparations et leurs applications en therapeutique
AU7089800A (en) 29 human cancer associated proteins
AU5685300A (en) Solid preparations containing paroxetine
EP1051966A3 (de) Kosmetische und/oder pharmazeutische Zubereitungen mit einem Gehalt an Alkyl- und/oder Alkenyloligoglykosiden, Fettsäurepartialglyceriden, Esterquats und hydroxyalkylertem Guar als Verdickungsmittel
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
AU7920198A (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
AU6687896A (en) Targeting of organs by immunoconjugates
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
WO1998051792A8 (en) Fac molecules and uses thereof
AU4426996A (en) Therapeutic compound - fatty acid conjugates
AUPN058695A0 (en) Therapeutic conjugates 8
AUPN058595A0 (en) Therapeutic conjugates 7
AUPN058395A0 (en) Therapeutic conjugates 5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties